(Q36926629)

17 August 2017

1 reference

title

COPD exacerbations: defining their cause and prevention (English)

1 reference

chronic obstructive pulmonary disease

17 August 2017

1 reference

1 reference

Jadwiga A Wedzicha

1

1 reference

PubMed ID

17765528

17 August 2017

Terence A R Seemungal

series ordinal

2

1 reference

PubMed ID

17765528

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

370

1 reference

17 August 2017

786-796

1 reference

17 August 2017

9589

1 reference

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Inflammatory changes, recovery and recurrence at COPD exacerbation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Toward a consensus definition for COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Airway eosinophilia in chronic bronchitis during exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Oxidative stress and airway inflammation in severe exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

The nature of small-airway obstruction in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Risk of myocardial infarction and stroke after acute infection or vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

COPD exacerbations . 3: Pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effects of exacerbations and seasonality on exhaled nitric oxide in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

COPD exacerbations . 2: aetiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Epidemiological relationships between the common cold and exacerbation frequency in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Viral etiology of acute exacerbations of COPD in Hong Kong.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Amplification of inflammation in emphysema and its association with latent adenoviral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Respiratory viral infections in adults with and without chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Antibiotics for exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Chlamydia pneumoniae and COPD exacerbation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Serological evidence of Legionella species infection in acute exacerbation of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Health effects of an air pollution episode in London, December 1991.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Air pollution and hospital admissions for chronic obstructive pulmonary disease in a subtropical city: Taipei, Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

[Respiratory and cardiovascular hospitalizations associated with air pollution in the city of São Paulo, Brazil].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Personal exposure to nitrogen dioxide and risk of airflow obstruction in asthmatic children with upper respiratory infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

COPD exacerbations: definitions and classifications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Risk factors of readmission to hospital for a COPD exacerbation: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Airway and systemic inflammation and decline in lung function in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Physical activity and hospitalization for exacerbation of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Exacerbations and time spent outdoors in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Frequency of venous thrombosis in patients with an exacerbation of chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Impact of influenza vaccination on major cause-specific mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immuno

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effect of beta-agonists on inflammatory cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

COPD exacerbations. 4: Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Effectiveness of innovations in nurse led chronic disease management for patients with chronic obstructive pulmonary disease: systematic review of evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Integrated care prevents hospitalisations for exacerbations in COPD patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961382-8

7 January 2021

Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study.

1 reference

12 December 2020

Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party

1 reference

12 December 2020

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

12 December 2020

Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels

1 reference

12 December 2020

10.1016/S0140-6736(07)61382-8

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17765528